https://www.marketscreener.com/news/kailera-makes-a-splash-on-nasdaq-as-anti-obesity-drug-frenzy-continues-ce7e50d3d980f52d
Kailera makes a splash on Nasdaq as anti-obesity drug frenzy continues | MarketScreener
Apr 17, 2026 - Kailera Therapeutics delivered a standout initial public offering on the Nasdaq, with its shares surging 62.5% in early trading. The company raised $625m by...
anti obesity drug
https://www.biospace.com/press-releases/can-fite-anti-obesity-drug-namodenoson-received-patent-allowance-in-australia
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia - BioSpace
anti obesity drug
https://www.goldmansachs.com/insights/articles/the-anti-obesity-drug-market-may-prove-smaller-than-expected
The anti-obesity drug market may prove smaller than expected | Goldman Sachs
Lower prices, higher competition, and insurance coverage are forecast to moderate the growth of the market for anti-obesity drugs worldwide.
anti obesity drug
https://pmc.ncbi.nlm.nih.gov/articles/PMC4665515/
Saffron: A Natural Potent Antioxidant as a Promising Anti-Obesity Drug - PMC
Obesity is associated with various diseases, particularly diabetes, hypertension, osteoarthritis and heart disease. Research on possibilities of herbal...
anti obesity drugsaffronnaturalpotentantioxidant
https://sciencedaily.com/releases/2024/08/240826193135.htm
One in 7 Medicare beneficiaries with high body mass index may qualify for anti-obesity drug |...
A new study estimates that 3.6 million Medicare beneficiaries are most likely to become eligible for semaglutide. The study also estimates eligibility and...